神经内分泌肿瘤64 cu-dotatate宠物:未来的详细比较112年与111 in-dtpa-octreotide病人。

文章的细节

引用

复制到剪贴板

具有一个克尼格U, Binderup T,莫滕森J, Oturai P,阁楼,Berthelsen AK,兰格西南,拉斯穆森P,硅碳棒D·冯·Benzon E, Hojgaard L·卡亚尔:A

神经内分泌肿瘤64 cu-dotatate宠物:未来的详细比较112年与111 in-dtpa-octreotide病人。

J诊断。2015年6月;56 (6):847 - 54。doi: 10.2967 / jnumed.115.156539。2015年5月7日Epub。

PubMed ID

25952736 (在PubMed

]

文摘

未标记的:神经内分泌肿瘤(网)可以使用放射性标记的可视化生长抑素类似物。我们以前所示(64)的临床潜力Cu-DOTATATE在小first-in-human可行性研究。本研究的目的是,在一个更大的潜在设计,在一对一的基础上比较的性能(64)Cu-DOTATATE和(111)In-diethylenetriaminepentaacetic酸(二乙三胺五醋酸)-octreotide ((111) In-DTPA-OC)为基础实现(64)Cu-DOTATATE常规。方法:我们前瞻性的112例病理证实的蚊帐gastroenteropancreatic或肺动脉起源。所有患者都经历了PET / CT (64) Cu-DOTATATE SPECT / CT和(111)In-DTPA-OC 60 d内,PET扫描获得202 h后注入兆贝可(范围183 - 232兆贝可)(64)Cu-DOTATATE诊断超声造影后CT扫描。患者随访42-60莫不符影像学表现的评价。McNemar检验法测试是用来比较的诊断性能。结果:八十七名患者的生活会宠物——SPECT-positive。未PET-negative SPECT-positive病例,而10假阴性SPECT病例使用宠物。(64)的诊断敏感性和准确性Cu-DOTATATE(97%)明显优于(111)的In-DTPA-OC(分别为87%和88%,P = 0.017)。 In 84 patients (75%), (64)Cu-DOTATATE identified more lesions than (111)In-DTPA-OC and always at least as many. In total, twice as many lesions were detected with (64)Cu-DOTATATE than with (111)In-DTPA-OC. Moreover, in 40 of 112 cases (36%) lesions were detected by (64)Cu-DOTATATE in organs not identified as disease-involved by (111)In-DTPA-OC. CONCLUSION: With these results, we demonstrate that (64)Cu-DOTATATE is far superior to (111)In-DTPA-OC in diagnostic performance in NET patients. Therefore, we do not hesitate to recommend implementation of (64)Cu-DOTATATE as a replacement for (111)In-DTPA-OC.

DrugBank数据引用了这篇文章

药物

铜oxodotreotide铜- 64